NCL

Across TCGA pan-cancer cohorts, NCL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCL data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NCL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCL expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where NCL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.865	0.503	.005	16	view →
PDAC	DFS	Median	II,III,IV	0.300	0.518	.005	14	view →
HNSC	DFS	Tertile	IV	0.628	0.903	.014	12	view →
CCRCC	DFS	Tertile	All	0.630	0.885	.030	2	view →
UCEC	OS	Quartile	All	0.919	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCL–LSCC (DFS)

Open the LSCC breakdown →